Osteoporosis Treatment Denosumab May Cause ANCA Vasculitis, Case Report Suggests
Denosumab, an approved treatment for osteoporosis, may sometimes trigger antineutrophil cytoplasmic antibody (ANCA) associated vasculitis with cytoplasmic ANCAs, a case study reports. While this treatment has been linked with vasculitis, this is the first report of a denosumab-derived cytoplasmic-ANCA vasculitis, the researchers say. The case study, “c-ANCA vasculitis…